Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

The drug adaptaquin blocks ATF4/CHOP-dependent pro-death Trib3 induction and protects in cellular and mouse models of Parkinson's disease.

Aimé P, Karuppagounder SS, Rao A, Chen Y, Burke RE, Ratan RR, Greene LA.

Neurobiol Dis. 2020 Mar;136:104725. doi: 10.1016/j.nbd.2019.104725. Epub 2020 Jan 3.

2.

Selenium Drives a Transcriptional Adaptive Program to Block Ferroptosis and Treat Stroke.

Alim I, Caulfield JT, Chen Y, Swarup V, Geschwind DH, Ivanova E, Seravalli J, Ai Y, Sansing LH, Ste Marie EJ, Hondal RJ, Mukherjee S, Cave JW, Sagdullaev BT, Karuppagounder SS, Ratan RR.

Cell. 2019 May 16;177(5):1262-1279.e25. doi: 10.1016/j.cell.2019.03.032. Epub 2019 May 2.

3.

Ferroptosis in Neurons and Cancer Cells Is Similar But Differentially Regulated by Histone Deacetylase Inhibitors.

Zille M, Kumar A, Kundu N, Bourassa MW, Wong VSC, Willis D, Karuppagounder SS, Ratan RR.

eNeuro. 2019 Feb 15;6(1). pii: ENEURO.0263-18.2019. doi: 10.1523/ENEURO.0263-18.2019. eCollection 2019 Jan-Feb.

4.

N-acetylcysteine targets 5 lipoxygenase-derived, toxic lipids and can synergize with prostaglandin E2 to inhibit ferroptosis and improve outcomes following hemorrhagic stroke in mice.

Karuppagounder SS, Alin L, Chen Y, Brand D, Bourassa MW, Dietrich K, Wilkinson CM, Nadeau CA, Kumar A, Perry S, Pinto JT, Darley-Usmar V, Sanchez S, Milne GL, Pratico D, Holman TR, Carmichael ST, Coppola G, Colbourne F, Ratan RR.

Ann Neurol. 2018 Dec;84(6):854-872. doi: 10.1002/ana.25356. Epub 2018 Nov 29.

5.
6.

Neuronal Death After Hemorrhagic Stroke In Vitro and In Vivo Shares Features of Ferroptosis and Necroptosis.

Zille M, Karuppagounder SS, Chen Y, Gough PJ, Bertin J, Finger J, Milner TA, Jonas EA, Ratan RR.

Stroke. 2017 Apr;48(4):1033-1043. doi: 10.1161/STROKEAHA.116.015609. Epub 2017 Mar 1.

7.

Bioactive Flavonoids and Catechols as Hif1 and Nrf2 Protein Stabilizers - Implications for Parkinson's Disease.

Smirnova NA, Kaidery NA, Hushpulian DM, Rakhman II, Poloznikov AA, Tishkov VI, Karuppagounder SS, Gaisina IN, Pekcec A, Leyen KV, Kazakov SV, Yang L, Thomas B, Ratan RR, Gazaryan IG.

Aging Dis. 2016 Dec 1;7(6):745-762. doi: 10.14336/AD.2016.0505. eCollection 2016 Dec.

8.

Exercise promotes the expression of brain derived neurotrophic factor (BDNF) through the action of the ketone body β-hydroxybutyrate.

Sleiman SF, Henry J, Al-Haddad R, El Hayek L, Abou Haidar E, Stringer T, Ulja D, Karuppagounder SS, Holson EB, Ratan RR, Ninan I, Chao MV.

Elife. 2016 Jun 2;5. pii: e15092. doi: 10.7554/eLife.15092.

9.

Therapeutic targeting of oxygen-sensing prolyl hydroxylases abrogates ATF4-dependent neuronal death and improves outcomes after brain hemorrhage in several rodent models.

Karuppagounder SS, Alim I, Khim SJ, Bourassa MW, Sleiman SF, John R, Thinnes CC, Yeh TL, Demetriades M, Neitemeier S, Cruz D, Gazaryan I, Killilea DW, Morgenstern L, Xi G, Keep RF, Schallert T, Tappero RV, Zhong J, Cho S, Maxfield FR, Holman TR, Culmsee C, Fong GH, Su Y, Ming GL, Song H, Cave JW, Schofield CJ, Colbourne F, Coppola G, Ratan RR.

Sci Transl Med. 2016 Mar 2;8(328):328ra29. doi: 10.1126/scitranslmed.aac6008.

10.

Metabolism and epigenetics in the nervous system: Creating cellular fitness and resistance to neuronal death in neurological conditions via modulation of oxygen-, iron-, and 2-oxoglutarate-dependent dioxygenases.

Karuppagounder SS, Kumar A, Shao DS, Zille M, Bourassa MW, Caulfield JT, Alim I, Ratan RR.

Brain Res. 2015 Dec 2;1628(Pt B):273-287. doi: 10.1016/j.brainres.2015.07.030. Epub 2015 Jul 29. Review.

11.

Hydroxamic acid-based histone deacetylase (HDAC) inhibitors can mediate neuroprotection independent of HDAC inhibition.

Sleiman SF, Olson DE, Bourassa MW, Karuppagounder SS, Zhang YL, Gale J, Wagner FF, Basso M, Coppola G, Pinto JT, Holson EB, Ratan RR.

J Neurosci. 2014 Oct 22;34(43):14328-37. doi: 10.1523/JNEUROSCI.1010-14.2014. Erratum in: J Neurosci. 2015 Jan 7;35(1):438.

12.

Antihelminthic benzimidazoles are novel HIF activators that prevent oxidative neuronal death via binding to tubulin.

Aleyasin H, Karuppagounder SS, Kumar A, Sleiman S, Basso M, Ma T, Siddiq A, Chinta SJ, Brochier C, Langley B, Haskew-Layton R, Bane SL, Riggins GJ, Gazaryan I, Starkov AA, Andersen JK, Ratan RR.

Antioxid Redox Signal. 2015 Jan 10;22(2):121-34. doi: 10.1089/ars.2013.5595.

13.

In vitro ischemia suppresses hypoxic induction of hypoxia-inducible factor-1α by inhibition of synthesis and not enhanced degradation.

Karuppagounder SS, Basso M, Sleiman SF, Ma TC, Speer RE, Smirnova NA, Gazaryan IG, Ratan RR.

J Neurosci Res. 2013 Aug;91(8):1066-75. doi: 10.1002/jnr.23204. Epub 2013 Mar 4.

14.

Sodium salicylate protects against rotenone-induced parkinsonism in rats.

Madathil SK, Karuppagounder SS, Mohanakumar KP.

Synapse. 2013 Aug;67(8):502-14. doi: 10.1002/syn.21658. Epub 2013 Mar 27.

PMID:
23447126
15.

Hypoxia-inducible factor prolyl hydroxylases as targets for neuroprotection by "antioxidant" metal chelators: From ferroptosis to stroke.

Speer RE, Karuppagounder SS, Basso M, Sleiman SF, Kumar A, Brand D, Smirnova N, Gazaryan I, Khim SJ, Ratan RR.

Free Radic Biol Med. 2013 Sep;62:26-36. doi: 10.1016/j.freeradbiomed.2013.01.026. Epub 2013 Jan 31. Review.

16.

Histone Deacetylase Inhibitors and Mithramycin A Impact a Similar Neuroprotective Pathway at a Crossroad between Cancer and Neurodegeneration.

Sleiman SF, Berlin J, Basso M, Karuppagounder SS, Rohr J, Ratan RR.

Pharmaceuticals (Basel). 2011 Aug 22;4(8):1183-1195.

17.

Hypoxia-inducible factor prolyl hydroxylase inhibition: robust new target or another big bust for stroke therapeutics?

Karuppagounder SS, Ratan RR.

J Cereb Blood Flow Metab. 2012 Jul;32(7):1347-61. doi: 10.1038/jcbfm.2012.28. Epub 2012 Mar 14. Review.

18.

Oxidant-induced changes in mitochondria and calcium dynamics in the pathophysiology of Alzheimer's disease.

Gibson GE, Karuppagounder SS, Shi Q.

Ann N Y Acad Sci. 2008 Dec;1147:221-32. doi: 10.1196/annals.1427.038. Review.

19.

Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease.

Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE.

Neurochem Int. 2009 Feb;54(2):111-8. doi: 10.1016/j.neuint.2008.10.008. Epub 2008 Nov 8.

20.

Thiamine deficiency induces oxidative stress and exacerbates the plaque pathology in Alzheimer's mouse model.

Karuppagounder SS, Xu H, Shi Q, Chen LH, Pedrini S, Pechman D, Baker H, Beal MF, Gandy SE, Gibson GE.

Neurobiol Aging. 2009 Oct;30(10):1587-600. doi: 10.1016/j.neurobiolaging.2007.12.013. Epub 2008 Apr 10.

Supplemental Content

Loading ...
Support Center